- Report
- June 2026
- 180 Pages
Global
From €5400EUR$5,950USD£4,612GBP
- Report
- June 2026
- 194 Pages
Global
From €3217EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP
- Report
- February 2026
- 250 Pages
Global
From €4075EUR$4,490USD£3,481GBP
- Report
- July 2026
- 248 Pages
Global
From €5310EUR$5,850USD£4,535GBP
- Report
- July 2025
- 188 Pages
Global
From €4084EUR$4,500USD£3,488GBP
- Report
- May 2026
- 145 Pages
Global
From €2722EUR$2,999USD£2,325GBP
€3630EUR$3,999USD£3,100GBP
- Report
- April 2026
- 294 Pages
Global
From €2269EUR$2,500USD£1,938GBP
- Report
- April 2026
- 160 Pages
Global
From €3013EUR$3,320USD£2,574GBP
€3767EUR$4,150USD£3,217GBP
- Report
- August 2025
- 182 Pages
Global
From €3218EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP
- Report
- May 2026
- 250 Pages
Global
From €4075EUR$4,490USD£3,481GBP
- Report
- April 2026
- 93 Pages
Global
From €3500EUR$4,131USD£3,094GBP
- Report
- March 2026
- 500 Pages
Global
From €4534EUR$4,995USD£3,872GBP
- Report
- March 2026
- 1100 Pages
Global
From €4534EUR$4,995USD£3,872GBP
- Report
- September 2025
Global
From €4356EUR$4,799USD£3,720GBP
- Report
- January 2026
- 182 Pages
Global
From €3218EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP
- Report
- August 2025
- 196 Pages
Global
From €3218EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP
- Report
- August 2025
- 191 Pages
Global
From €3218EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP
- Report
- June 2026
- 193 Pages
Global
From €3217EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP
- Report
- January 2026
- 193 Pages
Global
From €3218EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP
- Report
- January 2026
- 197 Pages
Global
From €3218EUR$3,545USD£2,748GBP
€3575EUR$3,939USD£3,054GBP

The Aptamer market is a subset of the biotechnology industry that focuses on the development and production of aptamers, which are short, single-stranded DNA or RNA molecules that can bind to specific targets. Aptamers are used in a variety of applications, including diagnostics, therapeutics, and research. Aptamers are often used as alternatives to antibodies, as they are more stable, easier to produce, and can be tailored to bind to a wide range of targets.
Aptamers are produced through a process called SELEX (Systematic Evolution of Ligands by Exponential Enrichment), which involves iterative cycles of selection and amplification of aptamers that bind to the desired target. This process is often automated, allowing for the rapid production of aptamers.
The Aptamer market is growing rapidly, driven by increasing demand for aptamers in research and clinical applications. Companies in the Aptamer market include Aptagen, Aptamer Solutions, Base Pair Biotechnologies, and Aptamer Group. Show Less Read more